Results

1–6 of 6 results for stargardt disease

Eighteen-Month Results From the Phase 1b-2 Study of Tinlarebant in Adolescent Subjects with Stargardt Disease
Quan Dong Nguyen, MD, MSc, FARVO, FASRS
Annual Meeting Talks
2023
MCO-010 Optogenetic Therapy for Severe Vision Loss in Stargardt Disease: 6-Month Outcomes From the Phase 2 STARLIGHT Trial
Allen C Ho, MD FASRS
Annual Meeting Talks
2023
Oral Gildeuretinol Acetate 14 mg Capsules Stalled Stargardt Disease Progression: Updates in the TEASE-3 Study
Michael Gorin, MD, PhD
Annual Meeting Talks
2024
Safety, Tolerability, and Efficacy of Tinlarebant: 24-Month Primary Outcomes of the Phase 2 Study in Adolescent Patients With Stargardt Disease
Quan Dong Nguyen, MD, MSc, FARVO, FASRS
Annual Meeting Talks
2024
Stargardt Disease
Filip Kecer
Retina Image Bank: Images of the Week
2022
Natural History of Untreated Atrophic Lesions in AMD and Stargardt Disease: A Meta-analysis
Lucian V. Del Priore, MD, PhD
On Demand Cases, Courses, and Papers
2019